Modulation of Folate Receptor Beta for Drug Targeting in Acute Myelogenous Leukemia
Explore this paper's citation graph
Summary
It is shown that the histone deacetylase (HDAC) inhibitors Trichostatin A (TSA), valproic acid (VPA) and FK228 potentiated ATRA induction of FR- β gene transcription and FR-β mRNA/protein expression, and the combination of ATRA and innocuous HDAC inhibitors may be expected to facilitate selectiveFR-β-targeted therapies in AML.
- Type
- dissertation
- Published
- 2005-01-01
- Cited by
- 0
- References
- 202
- Access
- Open access
- OpenAlex
- https://openalex.org/W78295568
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:68233600
Keywords
Trichostatin A, Histone deacetylase, Retinoic acid, Chromatin immunoprecipitation, Cancer research
References
- Transcription factors 3: nuclear receptors.
- Role of CBP/P300 in nuclear receptor signalling
- Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia
- Enhancement of folate receptor alpha expression in tumor cells through the glucocorticoid receptor: a promising means to improved tumor detection and targeting.
- The nuclear retinoid receptors.
- The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion.
- Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.
- Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients.
- Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells.
- Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia.
- Fusion between a novel Krüppel‐like zinc finger gene and the retinoic acid receptor‐alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia.
- Deacetylase enzymes: biological functions and the use of small-molecule inhibitors.
- IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases.
- Molecular cloning and characterization of the human folate-binding protein cDNA from placenta and malignant tissue culture (KB) cells.
- Characterization of the gene encoding a folate-binding protein expressed in human placenta. Identification of promoter activity in a G-rich SP1 site linked with the tandemly repeated GGAAG motif for the ets encoded GA-binding protein.
- Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab')2 antibody prolong host survival in a murine xenograft model.
- Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein.
- Cytotoxicity of momordin-folate conjugates in cultured human cells.
- Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein.
- The complete amino acid sequence of a human folate binding protein from KB cells determined from the cDNA.
Cited by
No citing papers recorded for this paper.
Related papers
- GSK3 is a regulator of RAR-mediated differentiation
- Abstract 5372: Novel and selective inhibitors of histone deacetylases (HDAC) 1 and 2 significantly enhance the activity of the DNA methyltransferase inhibitor azacitidine in acute myeloid leukemia (AML)
- Abstract B84: Novel and selective inhibitors of histone deacetylases (HDAC) 1 and 2 significantly enhance the activity of the DNA methyltransferase inhibitor azacitidine in acute myeloid leukemia (AML)
- FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
- All-trans retinoic acid and protein kinase C α/β1 inhibitor combined treatment targets cancer stem cells and impairs breast tumor progression
- Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia
- Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia
- The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
- A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations
- A novel glycogen synthase kinase-3 inhibitor optimized for acute myeloid leukemia differentiation activity